Comparative Pharmacology
Head-to-head clinical analysis: POLYSPORIN versus ZELSUVMI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: POLYSPORIN versus ZELSUVMI.
POLYSPORIN vs ZELSUVMI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Polysporin is a combination of polymyxin B and bacitracin. Polymyxin B disrupts bacterial cell membrane by binding to lipopolysaccharides, increasing permeability. Bacitracin inhibits bacterial cell wall synthesis by interfering with dephosphorylation of the lipid carrier in peptidoglycan synthesis.
Nucleoside analog inhibitor of RNA-dependent RNA polymerase (NS5B polymerase) of hepatitis C virus, incorporating into viral RNA and causing chain termination.
Apply a thin layer topically to the affected area 1 to 3 times daily. If using the ointment, cover with a sterile bandage if desired.
ZELSUVMI (berotralstat) 150 mg orally once daily with food.
None Documented
None Documented
Polymyxin B: 6–7 hours (impaired renal function: prolonged). Bacitracin: 1.5 hours (topical; not systemically absorbed).
Terminal elimination half-life is approximately 19.6 hours in healthy adults, supporting once-daily dosing.
Polysporin (polymyxin B/bacitracin) ophthalmic/otic/topical: Minimal systemic absorption. Renal elimination for absorbed fraction: <1% of dose.
Primarily renal excretion as unchanged drug; approximately 60% recovered in urine and 20% in feces over 72 hours.
Category C
Category C
Topical Antibiotic
Topical Antibiotic